Glibenclamide pharmacokinetics

Gerard J, Lefebvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 1984 27(2) 233-6. 

In a placebo-controlled study in six patients with type 2 diabetes, acarbose 300 mg/day for 7 days had no significant effect on the pharmacokinetics of a single dose of glibenclamide 5 mg (76). 

Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lucker PW, Fuder H. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol 1997 53(2) 149-52. 

Schulz E, Koch K, Schmidt FH. [Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone.] Eur J Clin Pharmacol 1971 4(l) 32-7. 

Coppack, S.W. Lant, A.F. McIntosh, C.S. Rodgers, A.V. Pharmacokinetic and pharmacod5Tiamicstudies of glibenclamide in non-insulin dependent diabetes mellitus. Br.J.Clin.PharmacoL, 1990, 29, 673-684 [plasma gliburnide (IS) LOD 10 ng/mL pharmacokinetics]... 

Phenprocoumon. The pharmacokinetics of glibenclamide remained unchanged by phenprocoumon. Similarly, the plasma levels and half-life of single doses of phenprocoumon did not differ between patients with type 2 diabetes managed by diet alone (12 patients) and those taking glibenclamide (9 patients). ... 

A brief report states that spirapril does not have a pharmacokinetic interaction with glibenclamide. The manufacturer of exenatide notes that, in a study in hypertensive patients exenatide 10 micrograms twice daily did not alter the steady-state AUC or maximum level of lisinopril 5 to 20 mg daily, but it did delay the time to maximum level by 2 hours. However, exenatide did not alter the blood-pressure lowering effect of lisino-pril. ... 

Glibenclamide (glyburide) causes a small reduction in valsartan plasma levels, but this is unlikely to be of any clinical significance. No clinically relevant pharmacokinetic interaction occurs between glibenclamide and candesartan or tehnisartan, or between tolbutamide and irbesartan. Eprosartan does not alter the efficacy of glibenclamide. Losartan and possibly eprosartan may reduce awareness of hypoglycaemic symptoms. 

Glibenclamide 3.5 mg daily did not significantly affect the pharmacokinetics of candesartan 16 mg daily, both given for 7 days, although the maximum plasma concentration of eandesartan was slightly inereased by 12%. The pharmacokinetics of glibenclamide were not altered by the can-desartan. ... 

Muck W, Heine Breuel H-P, Niklaus H, Horioilak J, Ahr G. The effect of multiple oral dosing of nimodipine on glibenclamide phannacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. IntJClinPharmaconher 995) 33, 89-94. 

Etodolac. Etodolac does not appear to affect the pharmacokinetics of glibenclamide. ... 

Lornoxicam. Lornoxicam 4 mg twice daily for 6 days had no effect on the pharmacokinetics of a single 5-mg dose of glibenclamide in 15 healthy subjects. The pharmacokinetics of lornoxicam also remained unchanged. However, concurrent use significantly increased plasma insulin levels (AUC 47%) and lowered serum glucose levels (8%), but this is probably not clinically important. ... 

Parecoxib. Valdecoxib, the active metabolite of parecoxib, does not appear to affect either the pharmacokinetics of glibenclamide or its effects on insulin or blood glucose levels. ... 

Orlistat improved glycaemic control, which resulted in the need to reduce the dose of glibenclamide (glyburide) or glipizide in almost half the patients in one study. In other studies, orlistat also reduced the dose requirement for metformin and for insulin. Orlistat did not alter the pharmacokinetics of glibenclamide or metformin. Orlistat and cimetidine may have contributed to a case of metformin-associated lactic acidosis. The manufacturers recom-... 

The small changes in the pharmacokinetics of glibenclamide caused by fluvastatin and simvastatin are not understood, but they do not appear to be elinieally signifieant. The interaction between atorvastatin or simvastatin and the thiazolidinediones is thought to involve the cytochrome P450 isoenzyme CYI TAd, although this is as yet unconfirmed. 

Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J. Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole. DiabetMed 9S7) 4, 245-7. 

There is no pharmacokinetic interaction between glibenclamide (glyburide) and pantoprazole, and pantoprazole does not alter the glucose-lowering effect of glibenclamide. 

---